Last $10.24 USD
Change Today -0.05 / -0.49%
Volume 73.1K
LJPC On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 08/19/14 All times are local (Market data is delayed by at least 15 minutes).

la jolla pharmaceutical co (LJPC) Snapshot

Open
$10.37
Previous Close
$10.29
Day High
$10.60
Day Low
$10.21
52 Week High
03/11/14 - $19.50
52 Week Low
08/20/13 - $3.00
Market Cap
156.0M
Average Volume 10 Days
134.8K
EPS TTM
$-21.14
Shares Outstanding
15.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LA JOLLA PHARMACEUTICAL CO (LJPC)

la jolla pharmaceutical co (LJPC) Related Bloomberg News

View More Bloomberg News

la jolla pharmaceutical co (LJPC) Related Businessweek News

No Related Businessweek News Found

la jolla pharmaceutical co (LJPC) Details

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for chronic organ failure and cancer. The company’s products include GCS-100 that is in Phase II clinical trial for the treatment of chronic kidney disease. It also provides LJPC-501, a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome; and LJPC-401, a peptide for the treatment of iron disorders. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

la jolla pharmaceutical co (LJPC) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $420.0K
Compensation as of Fiscal Year 2013.

la jolla pharmaceutical co (LJPC) Key Developments

La Jolla Pharmaceutical Co. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

La Jolla Pharmaceutical Co. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, loss from operations was $4.3 million against $3.2 million last year. Net loss attributable to common shareholders was $4.3 million, or $0.63 per share compared with $3.7 million, or $6.77 per share last year. For the six months, loss from operations was $9.4 million against $7.4 million last year. Net loss attributable to common shareholders was $9.4 million, or $1.16 per share compared with $7.9 million, or $17.57 per share last year. The increase in net loss attributable to common shareholders was primarily due to increases in research and development expenses related to the GCS-100 Phase 2 program in the treatment of CKD, as well as preclinical work on LJPC-1010 and LJPC-401.

La Jolla Pharmaceutical Co. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 03:05 PM

La Jolla Pharmaceutical Co. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 03:05 PM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: George F. Tidmarsh, Chief Executive Officer, President, Principal Financial Officer, Principal Accounting Officer, Secretary and Director.

LJPC Seeks Acquisitions

La Jolla Pharmaceutical Co. (NasdaqCM:LJPC) is looking for acquisition opportunities. LJPC intends to use the net proceeds from the underwritten offering for general corporate purposes, funding its ongoing and future clinical trials, general and administrative expenses and potential future acquisitions and other strategic purposes.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LJPC:US $10.24 USD -0.05

LJPC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LJPC.
View Industry Companies
 

Industry Analysis

LJPC

Industry Average

Valuation LJPC Industry Range
No financial data is available for LJPC.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LA JOLLA PHARMACEUTICAL CO, please visit www.ljpc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.